{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:53Z","timestamp":1793853833119,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although using Rituximab (RTX) and intravenous immunoglobulin (IVIg) alone or sequentially is a well-established treatment for several autoimmune diseases, the combination of these two forms of therapy is still rare, and its use is poorly studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To perform a systematic review on the use of RTX associated with IVIG in autoimmune conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, EMBASE, and Scielo databases were screened for articles on RTX plus IVIg in autoimmune diseases until May 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review encompassed 21 studies evaluating RTX and IVIg for autoimmune diseases. Ten studies focused on pemphigus, involving 85 patients with diverse subtypes (47 pemphigus vulgaris, 27 pemphigoids, and 11 other variants). Most were case reports or series, with one retrospective study including controls. Positive outcomes were reported across all but one case of paraneoplastic pemphigus. Infections, such as P. jirovecii pneumonia, were noted in three studies, highlighting a potential risk. The other 11 studies involved 24 patients with conditions like polyneuropathies, lupus with CNS involvement, and neuromyelitis optica. While most reported favorable outcomes, one trial on IVIg-dependent polyneuropathies found RTX ineffective in reducing IVIg needs. Adverse events included pneumonia, venous thrombosis with pulmonary embolism, and infusion reactions, demonstrating the need for careful monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RTX plus IVIg seems to be an alternative option for the treatment of refractory autoimmune diseases. However, more studies with a larger number of participants and in different autoimmune diseases are desired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-025-00450-x","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T15:56:17Z","timestamp":1742918177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-0844","authenticated-orcid":false,"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-3542","authenticated-orcid":false,"given":"Thelma Laroca","family":"Skare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"5 Pt 1","key":"450_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transpl. 2006;6(5 Pt 1):859\u201366. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x.","journal-title":"Am J Transpl"},{"issue":"20","key":"450_CR2","doi-asserted-by":"publisher","first-page":"15073","DOI":"10.1074\/jbc.M701654200","volume":"282","author":"J Du","year":"2007","unstructured":"Du J, Wang H, Zhong CB, Zhang M, Li B, Huo S, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282(20):15073\u201380. https:\/\/doi.org\/10.1074\/jbc.M701654200.","journal-title":"J Biol Chem"},{"key":"450_CR3","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","volume":"10","author":"C Kaegi","year":"2019","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. A systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. https:\/\/doi.org\/10.3389\/fimmu.2019.01990. eCollection 2019.","journal-title":"Front Immunol"},{"issue":"1","key":"450_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00063030-200216010-00005","volume":"16","author":"C Larroche","year":"2002","unstructured":"Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous Immunoglobulin action in the treatment of autoimmune disorders. BioDrugs. 2002;16(1):47\u201355. https:\/\/doi.org\/10.2165\/00063030-200216010-00005.","journal-title":"BioDrugs"},{"issue":"3","key":"450_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s1246-7820(03)00035-1","volume":"10","author":"J Bayry","year":"2003","unstructured":"Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous Immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10(3):165\u20139. https:\/\/doi.org\/10.1016\/s1246-7820(03)00035-1.","journal-title":"Transfus Clin Biol"},{"issue":"11","key":"450_CR6","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/trf.14841","volume":"58","author":"J MacIsaac","year":"2018","unstructured":"MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert KE, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune Globulin. Transfusion. 2018;58(11):2729\u201335. https:\/\/doi.org\/10.1111\/trf.14841.","journal-title":"Transfusion"},{"issue":"Suppl 1","key":"450_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2249.2009.04024.x","volume":"158","author":"HP Hartung","year":"2009","unstructured":"Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous Immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158(Suppl 1):23\u201333. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04024.x.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"450_CR8","first-page":"449","volume":"33","author":"L Iaccarino","year":"2015","unstructured":"Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449\u201356. PMID: 26053285.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"450_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune Globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0707894.","journal-title":"N Engl J Med"},{"key":"450_CR10","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1186\/s13643-020-01542-z","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1186\/s13643-020-01542-z.","journal-title":"BMJ"},{"issue":"5","key":"450_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","volume":"117","author":"CS Foster","year":"2010","unstructured":"Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous Immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2009.09.049.","journal-title":"Ophthalmology"},{"issue":"17","key":"450_CR12","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA, Posner MR, Ahmed AR, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune Globulin. N Engl J Med. 2006;355(17):1772\u20139. https:\/\/doi.org\/10.1056\/NEJMoa062930.","journal-title":"N Engl J Med"},{"key":"450_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s00105-007-1414-x","volume":"58","author":"C M\u00fchlhoff","year":"2007","unstructured":"M\u00fchlhoff C, Megahed M. Behandlung eines therapieresistenten pemphigus vulgaris Mit rituximab und Immunglobulinen. Hautarzt. 2007;58:924\u20136. https:\/\/doi.org\/10.1007\/s00105-007-1414-x.","journal-title":"Hautarzt"},{"issue":"3","key":"450_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","volume":"166","author":"RJ Feldman","year":"2012","unstructured":"Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. J Dermatol. 2012;166(3):511\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10658.x.","journal-title":"J Dermatol"},{"issue":"4","key":"450_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/1346-8138.13160","volume":"43","author":"C Namba","year":"2016","unstructured":"Namba C, Tohyama M, Hanakawa Y, Murakami M, Shirakata Y, Matsumoto T, Suemori K, Ishii N, Hashimoto T, Sayama K, Namba C, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: treatment with cyclosporin in addition to steroid, rituximab and intravenous Immunoglobulin. J Dermatol. 2016;43(4):419\u201322. https:\/\/doi.org\/10.1111\/1346-8138.13160.","journal-title":"J Dermatol"},{"issue":"2","key":"450_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/09546634.2018.1484873","volume":"30","author":"I Hamadah","year":"2019","unstructured":"Hamadah I, Chisti MA, Haider M, Binamer Y, Alajlan S, Aleyouni Y, Alfadley A. Rituximab\/IVIG in pemphigus - a 10-year study with a long follow-up. J Dermatolog Treat. 2019;30(2):170\u20135. https:\/\/doi.org\/10.1080\/09546634.2018.1484873.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"450_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","volume":"74","author":"AR Ahmed","year":"2016","unstructured":"Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74(4):700\u2013e83. https:\/\/doi.org\/10.1016\/j.jaad.2015.11.030.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"450_CR18","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/ICO.0000000000001024","volume":"35","author":"B Steger","year":"2016","unstructured":"Steger B, Madhusudan S, Kaye SB, Stylianides A, Romano V, Maqsood SE, Harper J, Ahmad S. Combined use of rituximab and intravenous Immunoglobulin for severe autoimmune cicatricial conjunctivitis. An interventional case series. Cornea. 2016;35(12):1611\u20134. https:\/\/doi.org\/10.1097\/ICO.0000000000001024.","journal-title":"Cornea"},{"issue":"4","key":"450_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ddg.14720","volume":"20","author":"CM Foschi","year":"2022","unstructured":"Foschi CM, Maloney C, Amber KT. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022;20(4):520\u20131. https:\/\/doi.org\/10.1111\/ddg.14720.","journal-title":"J Dtsch Dermatol Ges"},{"key":"450_CR20","doi-asserted-by":"publisher","unstructured":"Narayanan A, Pangti R, Agarwal S, Bhari N. Pemphigoid gestationis: a rare pregnancy dermatosis treated with a combination of IVIg and rituximab. BMJ Case Rep. 2021; 14(3): e24149 6. https:\/\/doi.org\/10.1136\/bcr-2020-241496","DOI":"10.1136\/bcr-2020-241496"},{"issue":"1","key":"450_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12185-011-0968-7","volume":"95","author":"J Muzaffar","year":"2012","unstructured":"Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous Immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012;95(1):102\u20136. https:\/\/doi.org\/10.1007\/s12185-011-0968-7.","journal-title":"Int J Hematol"},{"issue":"5","key":"450_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nrl.2013.12.022","volume":"30","author":"C Andr\u00e9s","year":"2015","unstructured":"Andr\u00e9s C, Teijeiro R, Saiz A, Fernandez P, S\u00e1nchez-Ram\u00f3n S. [Cambios En Las subpoblaciones de linfocitos B y T En El T\u00edtulo de anticuerpos anti-acuaporina-4 Tras El Tratamiento de Un brote Agudo Con inmunoglobulinas y rituximab]. Neurologia. 2015;30(5):276\u201382. https:\/\/doi.org\/10.1016\/j.nrl.2013.12.022.","journal-title":"Neurologia"},{"issue":"1","key":"450_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mus.20664","volume":"35","author":"KC Gorson","year":"2007","unstructured":"Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35(1):66\u20139. https:\/\/doi.org\/10.1002\/mus.20664.","journal-title":"Muscle Nerve"},{"issue":"1","key":"450_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13256-016-0917-4","volume":"10","author":"E Gertner","year":"2016","unstructured":"Gertner E, Rosenbloom MH. Susac syndrome with prominent dermatological findings and a prompt response to intravenous Immunoglobulin, steroids, and rituximab: a case report. J Med Case Rep. 2016;10(1):137. https:\/\/doi.org\/10.1186\/s13256-016-0917-4.","journal-title":"J Med Case Rep"},{"key":"450_CR25","doi-asserted-by":"crossref","unstructured":"Watson E, Minehan S, White R. It\u2019s never Lupus \u2026 until it is; Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis treated with intravenous immunoglobulin and rituximab: a case study. Neurology. 2017;88 (S-16):6\u2013191. 10.1212\/WNL.88.16_supplement.P6.191.","DOI":"10.1212\/WNL.88.16_supplement.P6.191"},{"issue":"1","key":"450_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/09546634.2016.117971","volume":"28","author":"A Oktem","year":"2017","unstructured":"Oktem A, Akay BN, Boyvat A, Kundakci N, Erdem C, Bostanc\u0131 S, et al. Long-term results of rituximab-intravenous Immunoglobulin combination therapy in patients with epidermolysis Bullosa acquisita resistant to conventional therapy. J Dermatolog Treat. 2017;28(1):50\u20134. https:\/\/doi.org\/10.1080\/09546634.2016.117971.","journal-title":"J Dermatolog Treat"},{"issue":"49","key":"450_CR27","doi-asserted-by":"publisher","first-page":"e8483","DOI":"10.1097\/MD.0000000000008483","volume":"96","author":"J Birnbaum","year":"2017","unstructured":"Birnbaum J, Lalji A, Piccione EA, Izbudak I. Magnetic resonance imaging of the spinal cord in the evaluation of 3 patients with sensory neuronopathies: diagnostic assessment, indications of treatment response, and impact of autoimmunity: A case report. Med (Baltim). 2017;96(49):e8483. https:\/\/doi.org\/10.1097\/MD.0000000000008483.","journal-title":"Med (Baltim)"},{"issue":"10","key":"450_CR28","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1093\/rheumatology\/keab069","volume":"60","author":"K Lima","year":"2021","unstructured":"Lima K, Tavee J, Dua A. Combination rituximab and intravenous Immunoglobulin for treatment of refractory vasculitic neuropathy: a case series. Rheumatology (Oxford). 2021;60(10):4884\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab069.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"450_CR29","doi-asserted-by":"publisher","first-page":"103011","DOI":"10.1016\/j.transci.2020.103011","volume":"60","author":"J Cid","year":"2021","unstructured":"Cid J, P\u00e9rez-Valencia AI, Torrente M\u00c1, \u00c1varez-Larr\u00e1n A, D\u00edaz-Ricart M, Esteve J, et al. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous Immunoglobulins (CASPERI). Transfus Apher Sci. 2021;60(1):103011. https:\/\/doi.org\/10.1016\/j.transci.2020.103011.","journal-title":"Transfus Apher Sci"},{"key":"450_CR30","doi-asserted-by":"publisher","unstructured":"Cheikh MM, Bahakim AK, Aljabri MK, Alharthi SM, Alharthi SM, Alsaeedi AK, et al. Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and Rituximab: An alternative to standard of care. Case Rep Rheumatol. 2022; 2022:5899188. https:\/\/doi.org\/10.1155\/2022\/5899188","DOI":"10.1155\/2022\/5899188"},{"issue":"3","key":"450_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/hematolrep14030036","volume":"14","author":"DR Castillo","year":"2022","unstructured":"Castillo DR, Sheth P, Nishino K, Stevens WT, Nguyen A, Romagnolo A, et al. Successful treatment of autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus in a post-heart transplant patient. Hematol Rep. 2022;14(3):261\u20134. https:\/\/doi.org\/10.3390\/hematolrep14030036.","journal-title":"Hematol Rep"},{"issue":"2","key":"450_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41433-018-0285-y","volume":"33","author":"M Salvi","year":"2019","unstructured":"Salvi M, Covelli D. B cells in graves\u2019 orbitopathy: more than just a source of antibodies? Eye (Lond). 2019;33(2):230\u20134. https:\/\/doi.org\/10.1038\/s41433-018-0285-y.","journal-title":"Eye (Lond)"},{"key":"450_CR33","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1984","unstructured":"Basta M, Dalakas MC. High-dose intravenous Immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1984;94:1729\u201335. https:\/\/doi.org\/10.1172\/JCI117520.","journal-title":"J Clin Invest"},{"key":"450_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","volume":"103","author":"HU Lutz","year":"2004","unstructured":"Lutz HU, Stammler P, Bianchi V, Tr\u00fceb RM, Hunziker T, Burger R, et al. Intravenously applied IgG stimulates complement Attenuation in a complement dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004;103:465\u201372. https:\/\/doi.org\/10.1182\/blood-2003-05-1530.","journal-title":"Blood"},{"key":"450_CR35","doi-asserted-by":"publisher","unstructured":"Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl Acad. Sci. USA. 2007;104:14104 -9. https:\/\/doi.org\/10.1073\/pnas.0700506104","DOI":"10.1073\/pnas.0700506104"},{"issue":"7","key":"450_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/intimm\/dxm052","volume":"19","author":"M Blank","year":"2007","unstructured":"Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol. 2007;19(7):857\u201365. https:\/\/doi.org\/10.1093\/intimm\/dxm052.","journal-title":"Int Immunol"},{"issue":"9","key":"450_CR37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1172\/JCI18838","volume":"113","author":"S Akilesh","year":"2004","unstructured":"Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004;113(9):1328\u201333. https:\/\/doi.org\/10.1172\/JCI18838.","journal-title":"J Clin Invest"},{"issue":"12","key":"450_CR38","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","volume":"115","author":"N Li","year":"2005","unstructured":"Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440\u201350. https:\/\/doi.org\/10.1172\/JCI24394.","journal-title":"J Clin Invest"},{"issue":"5503","key":"450_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484\u20136. https:\/\/doi.org\/10.1126\/science.291.5503.484.","journal-title":"Science"},{"issue":"6","key":"450_CR40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","volume":"98","author":"LK Kozicky","year":"2015","unstructured":"Kozicky LK, Zhao ZY, Menzies SC, Fidanza M, Reid GS, Wilhelmsen K, et al. Intravenous Immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. J Leukoc Biol. 2015;98(6):983\u201394. https:\/\/doi.org\/10.1189\/jlb.3VMA0315-078R.","journal-title":"J Leukoc Biol"},{"issue":"11","key":"450_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxx039","volume":"29","author":"C Galeotti","year":"2017","unstructured":"Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29(11):491\u20138. https:\/\/doi.org\/10.1093\/intimm\/dxx039.","journal-title":"Int Immunol"},{"issue":"3","key":"450_CR42","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1067\/mai.2002.127284","volume":"110","author":"Q Zhuang","year":"2002","unstructured":"Zhuang Q, Bisotto S, Fixman ED, Mazer B. Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous Immunoglobulin is not mediated through the inhibitory IgG receptor Fc gamma RIIb. J Allergy Clin Immunol. 2002;110(3):480\u20133. https:\/\/doi.org\/10.1067\/mai.2002.127284.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"450_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","volume":"135","author":"D Paquin Proulx","year":"2010","unstructured":"Paquin Proulx D, Aubin E, Lemieux R, Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous Immunoglobulins (IVIg). Clin Immunol. 2010;135(3):422\u20139. https:\/\/doi.org\/10.1016\/j.clim.2010.01.001.","journal-title":"Clin Immunol"},{"issue":"1","key":"450_CR44","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","volume":"15","author":"T Kelesidis","year":"2011","unstructured":"Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2\u201316. https:\/\/doi.org\/10.1016\/j.ijid.2010.03.025.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"450_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/CDLI.8.5.859-863.2001","volume":"8","author":"VG Hemming","year":"2001","unstructured":"Hemming VG. Use of intravenous Immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol. 2001;8(5):859\u201363. https:\/\/doi.org\/10.1128\/CDLI.8.5.859-863.2001.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"450_CR46","doi-asserted-by":"publisher","first-page":"e037306","DOI":"10.1136\/bmjopen-2020-037306","volume":"10","author":"J Hogan","year":"2020","unstructured":"Hogan J, Perez A, Sellier-Leclerc AL, Vrillon I, Broux F, Nobili F, et al. Efficacy and safety of intravenous Immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomized controlled trial. BMJ Open. 2020;10(9):e037306. https:\/\/doi.org\/10.1136\/bmjopen-2020-037306.","journal-title":"BMJ Open"},{"key":"450_CR47","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3389\/fimmu.2018.01189","volume":"9","author":"AR Ahmed","year":"2018","unstructured":"Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous Immunoglobulin. Front Immunol. 2018;9:1189. https:\/\/doi.org\/10.3389\/fimmu.2018.01189.","journal-title":"Front Immunol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00450-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T15:56:27Z","timestamp":1742918187000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-025-00450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00450-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the World Medical Association Declaration of Helsinki was followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Both authors wrote all this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and give their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}